VJToday

Advancing colorectal cancer screening: new technologies and lower age guidelines drive life-saving detection

Colorectal cancer (CRC) remains a formidable healthcare challenge despite being one of the most preventable cancers. While about 90% of cases are preventable1, CRC disease continues as the second leading cause of cancer death in the United States. The paradox is clear: effective screening saves lives, yet compliance remains disappointingly low, creating a critical gap between potential and reality in cancer prevention.

The screening compliance challenge

Despite overwhelming evidence supporting CRC screening effectiveness, significant barriers persist. The increase in the screening rate in the US between 2012 and 2018 represents an additional 9.3 million adults screened for colorectal cancer, yet the prevalence of up‐to‐date screening with any recommended test among individuals aged 45 years and older increased from 57% in 2019 to 59% in 2021.2 This modest improvement highlights the ongoing struggle to achieve optimal screening rates.

Multiple factors contribute to low compliance rates. Traditional colonoscopy, while considered the gold standard, presents substantial barriers including the need for bowel preparation, time off work, sedation requirements, and transportation logistics. These obstacles have prompted the development of alternative screening approaches designed to increase participation while maintaining clinical effectiveness.

The landscape of CRC screening has been transformed by innovative non-invasive tests that address traditional barriers to screening compliance. These advances represent a paradigm shift toward patient-centered care that prioritizes accessibility and convenience.

Blood-based screening: a game-changing breakthrough

One of the most significant breakthroughs in CRC screening is the Shield blood test, which received FDA approval in July 2024.3,4 This landmark approval represents the first FDA-cleared blood test specifically for CRC screening, offering unprecedented convenience for patients who have previously avoided screening.

The Shield test demonstrates reasonable sensitivity for detecting colorectal cancer, albeit lower at detecting precancerous polyps with only 13% sensitivity for advanced lesions.3 This limitation means that while the Shield test is suitable in detecting cancer, it is not as effective at preventing it. Nonetheless, the test serves a crucial role for individuals who refuse other screening methods.

Additional blood-based tests are in development, with BLUE-C results for Exact Sciences’ blood-based CRC screening test are now expected in the first half of 2025.17 These developments suggest a robust pipeline of blood-based screening options that could dramatically expand screening accessibility.

Enhanced stool-based testing

Stool-based testing has evolved significantly beyond simple fecal occult blood tests. This updated Cologuard test improves early detection, making it a strong alternative for people who want to screen at home.5 The Cologuard Plus test represents the latest advancement in multitarget stool DNA testing, combining traditional biomarkers with enhanced analytical capabilities.

ColoSense tests for RNA changes and blood in the stool and was approved in 2024, ColoSense blends traditional stool testing with RNA biomarkers, increasing accuracy without making the test more difficult to use.6 These innovations demonstrate the rapid evolution of home-based screening options that maintain ease of use while improving diagnostic accuracy.

The convenience of stool-based testing cannot be overstated. In the US, more than 96% of patients aged 45 and older have no out-of-pocket costs for screening with the Cologuard test5, removing financial barriers that might otherwise prevent screening participation.

AI-powered detection: enhancing endoscopic precision

Artificial intelligence has emerged as a transformative force in endoscopic CRC detection, addressing one of the most critical challenges in colonoscopy, the variability in adenoma detection rates among different endoscopists.

Computer-aided detection systems

Recent meta-analyses demonstrate the significant impact of AI on colonoscopy performance. Random-effects meta-analysis demonstrated a 20% increase in adenoma detection rate (risk ratio [RR], 1.20; 95% confidence interval [CI], 1.14-1.27; P < .01) and 55% decrease in adenoma miss rate (RR, 0.45; 95% CI, 0.32-0.64).7 This substantial improvement in detection rates has profound implications for cancer prevention.

The CADDIE™ computer-aided detection (CADe) device represents the first cloud-based Artificial Intelligence (AI) technology designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures, receiving FDA clearance.8 This milestone demonstrates the regulatory acceptance of AI-assisted endoscopy as a mainstream clinical tool.

Clinical impact and standardization

The clinical benefits of AI-assisted colonoscopy extend beyond simple polyp detection. CADe enhances adenoma detection in studies with low baseline ADR and increases the detection of inconspicuous polyps more frequently missed by endoscopists.9 This improvement is particularly significant because in regions or communities where access to highly trained interventionalists may be limited, AI can serve as a reliable and consistent ally in early polyp detection.

The standardization effect of AI technology addresses one of colonoscopy’s most significant limitations. This democratisation of expertise through AI could bridge the gap in healthcare equality, ensuring that more individuals receive accurate and timely diagnoses, ultimately reducing the burden of colorectal cancer on health systems.9

However, important limitations remain. Overall, advanced adenomas or colorectal cancers were found in about 34% of participants in both groups in the largest clinical trial to date,10 indicating that while AI improves detection of smaller lesions, its impact on clinically significant advanced adenomas requires further investigation.

The push for lower screening age guidelines

The recommendation to begin CRC screening at age 45 rather than 50 represents one of the most significant shifts in screening guidelines in recent decades, driven by alarming epidemiological trends in younger populations.

Epidemiological justification

The rationale for lowering the screening age is compelling. While death rates from CRC have declined in older adults over the past few decades, since the mid-2000s they have been rising among people under the age of 55. More specifically, people who were born between 1981 and 1996 have twice the risk of CRC compared to people born in 1950.1

The rates of diagnosis in people under the age of 55 have been steadily increasing. To improve the chances of finding colorectal cancer in earlier stages and in a younger population, the recommended screening age was recently lowered to 45.14 This change reflects the recognition that waiting until age 50 may miss critical opportunities for early detection in younger adults.

Evidence supporting earlier screening

Clinical evidence validates the effectiveness of screening younger populations. Adults ages 45 to 49 have a colorectal cancer risk that is similar to what we see in adults age 50, according to recent Kaiser Permanente research.12 The study found that colorectal cancer detection rates were similar: 2.8% of those ages 45 to 49 and 2.7% of those age 50 received a cancer diagnosis following their colonoscopy.

The guideline change has gained widespread acceptance. The USPSTF recommends offering colorectal cancer screening starting at age 45 years11, representing a shift from their previous recommendation of age 50. This change is supported by modeling performed by the Cancer Intervention and Surveillance Modeling Network (CISNET) suggests that starting colorectal cancer screening at age 45 years may moderate the increasing incidence in younger populations.11

Cost-effectiveness and healthcare impact

The economic implications of expanded screening programs are substantial. Implementation of CADe detection in a US population resulted in a yearly additional prevention of 7194 colorectal cancer cases and 2089 related deaths, with cost savings of USD 290 million.9 This analysis demonstrates that despite initial increased costs from detecting more adenomas, the long-term economic benefits are significant.

Treating late-stage colorectal cancer can cost up to three times more than early-stage treatment, emphasizing the economic benefits of widespread screening programs.3 This cost differential provides strong economic justification for investments in improved screening technologies and expanded access.

Future directions and emerging technologies

The future of CRC screening continues to evolve rapidly. At-home stool-based tests, such as FIT and Cologuard, are gaining popularity for their convenience and effectiveness, boosting screening compliance rates.3 The development of multi-cancer early detection tests also holds promise for comprehensive screening approaches that could detect CRC alongside other cancer types.16

Capsule colonoscopy and advanced imaging techniques represent additional frontiers in screening technology.16 These approaches could further reduce the invasiveness of screening while maintaining diagnostic accuracy, potentially addressing remaining barriers to screening participation.

Conclusion

The landscape of colorectal cancer screening stands at a transformative juncture. While compliance challenges persist, the convergence of innovative non-invasive testing options, AI-enhanced endoscopic detection, and evidence-based recommendations for earlier screening creates unprecedented opportunities for improving outcomes. The key to maximizing these advances lies in ensuring equitable access to these technologies while maintaining focus on the fundamental goal of increasing rates of screening.

The evolution from a one-size-fits-all approach to personalized screening strategies, combined with technological innovations that address traditional barriers, offers genuine hope for closing the gap between the potential and reality of CRC prevention. Success will ultimately be measured not by the sophistication of our technologies, but by their ability to save lives through increased screening participation and improved early detection.

References

  1. Pfizer. Colorectal Cancer Screening Guidelines Have Changed—What You Need to Know. Available at: https://www.pfizer.com/news/announcements/colorectal-cancer-screening-guidelines-have-changed-what-you-need-know. Accessed June 10, 2025.
  2. American Cancer Society National Colorectal Cancer Roundtable. Data and Progress. Available at: https://nccrt.org/our-impact/data-and-progress/. Published February 20, 2025. Accessed June 10, 2025.
  3. ColonoscopyAssist. Latest Advancements in Colorectal Cancer Screening for 2025. Available at: https://colonoscopyassist.com/blog/latest-advancements-in-colorectal-cancer-screening-for-2025/. Published January 31, 2025. Accessed June 10, 2025.
  4. National Cancer Institute. Shield Blood Test Approved for Colorectal Cancer Screening. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2024/shield-blood-test-colorectal-cancer-screening. Accessed June 10, 2025.
  5. Exact Sciences Corporation. Exact Sciences Launches the Cologuard Plus Test, Transforming Colorectal Cancer Screening. Available at: https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-the-cologuard-plus-test-transforming-colorectal-cancer-screening. Accessed June 10, 2025.
  6. American Cancer Society. Colorectal Cancer Screening Tests. Available at: https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/screening-tests-used.html. Accessed June 10, 2025.
  7. Ahmad OF, Mori Y, Misawa M, et al. Use of artificial intelligence improves colonoscopy performance in adenoma detection: a systematic review and meta-analysis. Gastrointest Endosc. 2025. doi:10.1016/S0016-5107(24)03471-0.
  8. Olympus Corporation. First Cloud-Based AI Endoscopy System for Colonoscopy Receives FDA Clearance. Available at: https://www.olympus-global.com/news/2024/nr02743.html. Published September 5, 2024. Accessed June 10, 2025.
  9. Young E, Edwards L, Singh R. The Role of Artificial Intelligence in Colorectal Cancer Screening: Lesion Detection and Lesion Characterization. Cancers (Basel). 2023;15(21):5126. doi:10.3390/cancers15215126.
  10. National Cancer Institute. CAD-Aided Colonoscopy and Advanced Adenomas. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2023/colonoscopy-cad-artificial-intelligence. Accessed June 10, 2025.
  11. US Preventive Services Task Force. Recommendation: Colorectal Cancer: Screening. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening. Published May 18, 2021. Accessed June 10, 2025.
  12. Kaiser Permanente Division of Research. Younger adults benefit from updated colorectal cancer screening guidelines. Available at: https://divisionofresearch.kaiserpermanente.org/45-49-colorectalcancer-screening/. Published October 25, 2024. Accessed June 10, 2025.
  13. RWJBarnabas Health. 45 is the New 50 for Colorectal Cancer Screening. Available at: https://www.rwjbh.org/blog/2025/march/45-is-the-new-50-for-colorectal-cancer-screening/. Accessed June 10, 2025.
  14. Gastroenterology Consultants of San Antonio. Colorectal Cancer Screening Guidelines for 2025. Available at: https://www.gastroconsa.com/colorectal-cancer-screening-guidelines-for-2025/. Published February 18, 2025. Accessed June 10, 2025.
  15. American Cancer Society. Colorectal Cancer Guideline. Available at: https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html. Accessed June 10, 2025.
  16. Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022;19(8):521-531. doi:10.1038/s41575-022-00612-y.
  17. Exact Sciences Corporation. Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024. Available at: https://www.exactsciences.com/newsroom/press-releases/Exact%20Sciences%20Presents%20Data%20Demonstrating%20Advancement%20in%20Blood-based%20Colorectal%20Cancer%20Screening%20at%20ESMO%202024. Accessed June 10, 2025.